Research programme: CD38 antibody therapeutics - Amorfix Life Sciences

Drug Profile

Research programme: CD38 antibody therapeutics - Amorfix Life Sciences

Latest Information Update: 18 Dec 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; QED Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Multiple myeloma

Most Recent Events

  • 18 Dec 2014 Suspended for Multiple myeloma in Canada (Parenteral)
  • 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012. http://www.amorfix.com
  • 24 Jun 2010 Early research in Multiple myeloma in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top